1-8 of 8
Ryuichiro Nakai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B037: The establishment and evaluation of anti-ASC amino acid transporter 2 (ASCT2) antibody as a novel therapeutic antibody for gastric cancer

Free
Aya Sasakawa, Kenta Hosomi, Toshihiko Ishii, Hiroshi Ando, Masayo Suzuki, Minami Imaizumi, Jian Zou, Noriyuki Kasai, Kazuya Yamano, Kazuyasu Nakamura, Ryuichiro Nakai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B037.
https://doi.org/10.1158/1535-7163.TARG-17-B037
Published: 01 January 2018
View article titled, Abstract B037: The establishment and evaluation of anti-ASC amino acid transporter 2 (ASCT2) antibody as a novel therapeutic antibody for gastric cancer
Journal Articles

The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase

Free
Ryoko Okada-Iwasaki, Yuichi Takahashi, Yasuo Watanabe, Hiroshi Ishida, Jun-ichi Saito, Ryuichiro Nakai, Akira Asai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1525–1534.
https://doi.org/10.1158/1535-7163.MCT-15-0938
Published: 05 July 2016
View article titled, The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase
Open the PDF for The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase in another window
Includes: Supplementary data
Journal Articles

Abstract C123: A novel anti-FOLR1 antibody developed with AccretaMab® technology, KHK2805, exhibits markedly high ADCC/CDC activity and a tolerable safety profile in preclinical models

Free
Munetoshi Ando, Keiko Nagata, Hiroshi Ando, Mariko Nakano, Naoya Kameyama, Tsuguo Kubota, Maiko Adachi, Yui Suzuki, Kazuyasu Nakamura, Toshihiko Ishii, Ryuichiro Nakai, Takeshi Takahashi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C123.
https://doi.org/10.1158/1535-7163.TARG-15-C123
Published: 01 December 2015
View article titled, Abstract C123: A novel anti-FOLR1 antibody developed with AccretaMab® technology, KHK2805, exhibits markedly high ADCC/CDC activity and a tolerable safety profile in preclinical models
Journal Articles

Abstract C124: A novel anti-FOLR1 antibody developed with AccretaMab® technology, KHK2805, exhibits potent anti-cancer activity against ovarian cancer samples with the FOLR1 expression

Free
Kaito Nihira, Munetoshi Ando, Keiko Nagata, Maiko Adachi, Yui Suzuki, Yutaka Kanda, Takeshi Oshima, Ken-ichiro Nan-ya, Masanori Hiura, Toshihiko Ishii, Ryuichiro Nakai, Takeshi Takahashi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C124.
https://doi.org/10.1158/1535-7163.TARG-15-C124
Published: 01 December 2015
View article titled, Abstract C124: A novel anti-FOLR1 antibody developed with AccretaMab® technology, KHK2805, exhibits potent anti-cancer activity against ovarian cancer samples with the FOLR1 expression
Journal Articles

Abstract A155: Small molecule metabolic inhibitors, compound A and the derivatives specifically inhibit the cell growth of Ewing's sarcoma cells harbor EWS-FLI1 in vitro and in vivo

Free
Hiromichi Kosaka, Yasuo Watanabe, Michihiro Maemoto, Masamori Sugawara, Miwa Watanabe, Yoko Ono, Yoshisuke Nakasato, Masahiro Matsubara, Ryuichiro Nakai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A155.
https://doi.org/10.1158/1535-7163.TARG-15-A155
Published: 01 December 2015
View article titled, Abstract A155: Small molecule metabolic inhibitors, compound A and the derivatives specifically inhibit the cell growth of Ewing's sarcoma cells harbor EWS-FLI1 in vitro and in vivo
Journal Articles

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models

Free
Xiang S. Ye, Li Fan, Robert D. Van Horn, Ryuichiro Nakai, Yoshihisa Ohta, Shiro Akinaga, Chikara Murakata, Yoshinori Yamashita, Tinggui Yin, Kelly M. Credille, Gregory P. Donoho, Farhana F. Merzoug, Heng Li, Amit Aggarwal, Kerry Blanchard, Eric H. Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2463–2472.
https://doi.org/10.1158/1535-7163.MCT-15-0241
Published: 03 November 2015
View article titled, A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
Open the PDF for A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models in another window
Includes: Supplementary data
Journal Articles

Abstract C245: Discovery and characterization of a new Wnt/β-catenin pathway inhibitor targeting tankyrase.

Free
Ryoko Okada, Yuichi Takahashi, Yasuo Watanabe, Hiroshi Ishida, Junichi Saito, Ryuichiro Nakai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C245.
https://doi.org/10.1158/1535-7163.TARG-13-C245
Published: 01 November 2013
View article titled, Abstract C245: Discovery and characterization of a new Wnt/β-catenin pathway inhibitor targeting tankyrase.
Journal Articles

Abstract A62: A novel Eg5 inhibitor that causes mitotic arrest leading to rapid cancer cell death shows broad‐spectrum antitumor activity in preclinical xenograft tumor models

Free
Xiang S. Ye, Li Fan, Robert Van Horn, Tinggui Yin, Ryuichiro Nakai, Yoshihisa Ohta, Kelly Credille, Gregory Donoho, Shiro Akinaga, Chikara Murakata, Everett Perkins, Scott Ocheltree, Yoshinori Yamashita, Kerry Blanchard, Eric Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A62.
https://doi.org/10.1158/1535-7163.TARG-09-A62
Published: 10 December 2009
View article titled, Abstract A62: A novel Eg5 inhibitor that causes mitotic arrest leading to rapid cancer cell death shows broad‐spectrum antitumor activity in preclinical xenograft tumor models